XJPX7749
Market cap279mUSD
Jan 17, Last price
2,600.00JPY
1D
0.31%
1Q
-7.87%
Jan 2017
-43.29%
IPO
-12.61%
Name
Medikit Co Ltd
Chart & Performance
P/E
14.22
P/S
2.00
EPS
182.85
Div Yield, %
4.01%
Shrs. gr., 5y
—
Rev. gr., 5y
4.99%
Revenues
21.85b
+1.13%
Net income
3.07b
+7.15%
CFO
4.83b
+7.90%
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 07, 2025
Profile
Medikit Co.,Ltd. engages in the manufacture and sale of vascular access medical devices. The company offers IV catheters, such as Supercath 5, Supercath Z3V, and Supercath Ztu-V; hemodialysis products, including Supercath PRO, Supercath NEO, and Supercath Clampcath; and intervention products comprising Supersheath and Mongoose. Its products are used in anesthetic departments, operating theaters, ICUs, and dialysis and cardiology units. The company markets its products through distributors in approximately 20 countries and territories in the European Union and on the American continent. Medikit Co.,Ltd. was founded in 1973 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 21,850,545 1.13% | 21,607,233 7.33% | 20,130,697 4.24% | ||
Cost of revenue | 17,123,000 | 17,543,069 | 15,803,553 | ||
Unusual Expense (Income) | |||||
NOPBT | 4,727,545 | 4,064,164 | 4,327,144 | ||
NOPBT Margin | 21.64% | 18.81% | 21.50% | ||
Operating Taxes | 1,705,693 | 1,426,749 | 1,479,786 | ||
Tax Rate | 36.08% | 35.11% | 34.20% | ||
NOPAT | 3,021,852 | 2,637,415 | 2,847,358 | ||
Net income | 3,069,466 7.15% | 2,864,589 -4.29% | 2,993,017 12.56% | ||
Dividends | (1,751,742) | (1,509,626) | (834,717) | ||
Dividend yield | 3.57% | 3.68% | 2.13% | ||
Proceeds from repurchase of equity | (4,832,351) | (66,516) | |||
BB yield | 9.85% | 0.17% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 816,130 | 890,023 | 826,315 | ||
Net debt | (26,073,058) | (28,540,374) | (29,111,015) | ||
| Cash flow | |||||
Cash from operating activities | 4,834,465 | 4,480,319 | 3,153,557 | ||
CAPEX | (1,688,000) | (1,025,715) | (1,784,549) | ||
Cash from investing activities | 3,230,735 | (3,582,343) | (1,719,622) | ||
Cash from financing activities | (6,584,093) | (1,509,626) | (901,234) | ||
FCF | 3,336,655 | 3,132,725 | 2,035,821 | ||
| Balance | |||||
Cash | 25,111,087 | 27,592,949 | 28,118,088 | ||
Long term investments | 961,971 | 947,425 | 992,927 | ||
Excess cash | 24,980,531 | 27,460,012 | 28,104,480 | ||
Stockholders' equity | 41,067,486 | 40,150,947 | 38,649,673 | ||
Invested Capital | 19,964,139 | 19,956,380 | 17,889,637 | ||
ROIC | 15.14% | 13.94% | 16.00% | ||
ROCE | 10.44% | 8.51% | 9.40% | ||
| EV | |||||
Common stock shares outstanding | 16,331 | 16,784 | 16,801 | ||
Price | 3,005.00 23.00% | 2,443.00 4.94% | 2,328.00 -28.59% | ||
Market cap | 49,074,655 19.68% | 41,004,033 4.84% | 39,112,728 -28.99% | ||
EV | 23,001,597 | 12,463,659 | 10,001,713 | ||
EBITDA | 6,272,201 | 5,387,890 | 5,597,051 | ||
EV/EBITDA | 3.67 | 2.31 | 1.79 | ||
Interest | 7,621 | 7,549 | 7,362 | ||
Interest/NOPBT | 0.16% | 0.19% | 0.17% | ||